US Code

Public Law 119-102 (07/12/2026)

42 U.S.C. § 285a–10

Research, information, and education with respect to blood cancer

Section text and notes

(a)

Joe Moakley Research Excellence Program

(1)

In general

The Director of NIH shall expand, intensify, and coordinate programs for the conduct and support of research with respect to blood cancer, and particularly with respect to leukemia, lymphoma, and multiple myeloma.

(2)

Administration

The Director of NIH shall carry out this subsection through the Director of the National Cancer Institute and in collaboration with any other agencies that the Director determines to be appropriate.

(b)

Geraldine Ferraro Cancer Education Program

(1)

In general

The Secretary shall direct the appropriate agency within the Department of Health and Human Services, in collaboration with the Director of NIH, to establish and carry out a program to provide information and education for patients and the general public with respect to blood cancer, and particularly with respect to the treatment of leukemia, lymphoma, and multiple myeloma.

(2)

Administration

The Agency determined by the Secretary under paragraph (1) shall carry out this subsection in collaboration with private health organizations that have national education and patient assistance programs on blood-related cancers.

July 1, 1944, ch. 373 Pub. L. 107–172, § 3116 Stat. 541 Pub. L. 109–482, title I, § 103(b)(17)120 Stat. 3688 Pub. L. 115–180, title II, § 204(a)132 Stat. 1390 (, title IV, § 417D, as added , , ; amended , , ; , , .)

Editorial Notes

Amendments

Pub. L. 115–180Pub. L. 107–172, § 32018— made technical correction to directory language of , which enacted this section.

Pub. L. 109–482, § 103(b)(17)(A)2007—Subsec. (a)(3). , struck out heading and text of par. (3). Text read as follows: “For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.”

Pub. L. 109–482, § 103(b)(17)(B)Subsec. (b)(3). , struck out heading and text of par. (3). Text read as follows: “For the purpose of carrying out this subsection, there is authorized to be appropriated such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year. Such authorizations of appropriations are in addition to other authorizations of appropriations that are available for such purpose.”

Statutory Notes and Related Subsidiaries

Effective Date of 2018 Amendment

Pub. L. 115–180, title II, § 204(b)132 Stat. 1390

section 3 of Pub. L. 107–172Public Law 107–172116 Stat. 541 “The amendment made by subsection (a) [amending ] shall take effect as if included in section 3 of the Hematological Cancer Research Investment and Education Act of 2002 (; ) [enacting this section].”
, , , provided that:

Effective Date of 2007 Amendment

Pub. L. 109–482section 109 of Pub. L. 109–482section 281 of this titleAmendment by applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see , set out as a note under .

Congressional Findings

Pub. L. 107–172, § 2116 Stat. 541

“Congress finds that:
“(1)
An estimated 109,500 people in the United States will be diagnosed with leukemia, lymphoma, and multiple myeloma in 2001.
“(2)
New cases of the blood cancers described in paragraph (1) account for 8.6 percent of new cancer cases.
“(3)
Those devastating blood cancers will cause the deaths of an estimated 60,300 persons in the United States in 2001. Every 9 minutes, a person in the United States dies from leukemia, lymphoma, or multiple myeloma.
“(4)
While less than 5 percent of Federal funds for cancer research are spent on those blood cancers, those blood cancers cause 11 percent of all cancer deaths in the United States.
“(5)
Increased Federal support of research into leukemia, lymphoma, and multiple myeloma has resulted and will continue to result in significant advances in the treatment, and ultimately the cure, of those blood cancers as well as other cancers.”
, , , provided that: